As the "black-box" problem creates challenges for AI, explainable AI can help reshape business-to-business operations by ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

A New Risk Landscape. As digital payments surge in India, so does the threat from increasingly sophisticated fraud schemes. The Reserve Bank of India (RBI) recently warned lenders ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

AI & Humanoids Artificial Intelligence may prove to be a more significant milestone than the harnessing of fire, or the invention of the wheel. It's the fastest-evolving technology the world has ...

Determining whether or not an image was created by generative AI is harder than ever, but it's still possible if you look out for these telltale signs. My title is Senior Features Writer ...

While a handful of technology names seem to dominate the space currently, investors looking to invest in AI may be wondering which companies are likely to do better as the field evolves.

Add a description, image, and links to the gcp-vertex-ai topic page so that developers can more easily learn about it.